Top Markets
Coin of the day
Intercept Pharmaceuticals, Inc. Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals, Inc.

ICPT
株式のランク #12019
Intercept Pharmaceuticals, Inc. is a biopharmaceutical firm specializing in the... Intercept Pharmaceuticals, Inc. is a biopharmaceutical firm specializing in the advancement and market launch of therapies designed to treat progressive, non-viral liver conditions. Its operational reach spans the United States, Europe, and Canada. The company currently markets Ocaliva, a medication functioning as a farnesoid X receptor (FXR) agonist. This drug is approved for the treatment of primary biliary cholangitis (PBC) in adults, specifically when administered alongside ursodeoxycholic acid. Beyond its existing approved indications, Intercept is actively investigating Ocaliva's potential for additional uses, notably including nonalcoholic steatohepatitis (NASH). Concurrently, it is progressing other drug candidates through various clinical and preclinical stages of development. In a collaborative effort, the company holds a licensing agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. Intercept distributes its products through a dual approach, utilizing both its proprietary commercial organization and a network of external third-party distributors. The company was founded in 2002 and is headquartered in New York, New York.
株価
$19.00
最終同期: 2023-11-14
時価総額
$629.64M
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Intercept Pharmaceuticals, Inc. (ICPT)

カテゴリー

Intercept Pharmaceuticals, Inc.(ICPT)の配当利回りの履歴
Intercept Pharmaceuticals, Inc.(銘柄コード: ICPT)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Intercept Pharmaceuticals, Inc.(ICPT)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)